Sino Biopharm Shares Down 14% In Hong Kong

Chinese drug manufacturer Sino Biopharmaceutical Ltd. Hong Kong fell 14 percent after its third-quarter earnings fell short of expectations, partly due to the impact of a centralized drug purchase program on prices.

 

According to Bloomberg, this will be the worst reaction to quarterly earnings reports since March 2010. The stock halted its decline to 11.5% as of 11:26 a.m. local time, its biggest decline since December 2018 on an intraday basis.

 

"The drop in results was caused by the double whammy of centralized procurement, which lowered drug prices, and the pandemic, which led to weak hospital traffic and hurt drug sales”" says Carol Dow, analyst at UOB Kay Hian Investment Co. " I expect that headwinds will continue in the first quarter of next year.”

 

Since the end of 2018, China has been driving down generic drug prices through a fierce bidding process for public hospital supply contracts. This exercise, which covers everything from chemotherapy drugs to medications for hypertension and erectile dysfunction , has in some cases led to price drops of more than 90%.

 

Beijing wants to cut spending on generic drugs by tens of billions of dollars to refocus funds on new, high-tech treatments for life-threatening diseases such as cancer. This process has reduced the profits of global companies in China for their traditional medicines, which are no longer under patent protection, resulting in a significant reduction in revenue.

 


Sino Biopharm said in its earnings report that it expected the effects of China's latest round of centralized drug purchases, which cut prices by an average of 53%, to materialize in the latest quarter.

 

In a research note, Daiwa analysts led by Dennis Yip noted that the company's revenue for the first nine months fell by 6% year-on-year. Without taking into account the impact of the procurement program, the company would have recorded a 13% increase in revenue, the note says.

 

Sino Biopharm was among the top performers on the Hang Seng index in the first half of the year, rising 34%. The stock has lost more than a third of its value since its all-time high in late July.

01 December, 2020
357
views

Read more:

Tesla will climb 8% to an all-time high of $ 900 as stock rallies help boost fundraising.

12 January, 2021

Global Stocks Rise After UK Travel Rules Eased

29 December, 2020

Three trend reversals that will define the market in early 2021

22 December, 2020

Modest market return in 2021 could disappoint worried investors

15 December, 2020

One stock market valuation indicator reached the highest point

08 December, 2020

Goldman Sachs Group Inc. plans to create a European stock trading platform

24 November, 2020

Encouraging results from Moderna vaccine trials have renewed hope in the tourism sector. #INDU

17 November, 2020

Oil prices fall on the eve of progress in the creation of the Covid-19 vaccine

10 November, 2020

US equities rose on Monday

03 November, 2020

Asia will be resistant to the second wave of coronavirus.

28 October, 2020

Oil prices fall for the fourth day

20 October, 2020

World stock indices are showing growth again. GOLD

13 October, 2020

World stock indices are growing

29 September, 2020

News overview for today

22 September, 2020

Hedge Funds Cut Their Optimistic Crude Oil Rates

15 September, 2020

David Trainer's opinion on Tesla shares

08 September, 2020

An urgent notification from the FXspace universe! Split of Apple and Tesla shares. #AAPL

01 September, 2020

Arrange a call